<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02282826</url>
  </required_header>
  <id_info>
    <org_study_id>TDU13475</org_study_id>
    <secondary_id>2014-001591-61</secondary_id>
    <secondary_id>U1111-1155-6252</secondary_id>
    <nct_id>NCT02282826</nct_id>
  </id_info>
  <brief_title>A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Single Intravenous and Subcutaneous Doses of GZ402668 in Men and Women With Progressive Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To assess the safety and tolerability of GZ402668 after ascending single intravenous (IV) and&#xD;
      subcutaneous (SC) doses in men and women with progressive multiple sclerosis.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      To assess the following in men and women with progressive multiple sclerosis:&#xD;
&#xD;
        -  The pharmacokinetic (PK) parameters of GZ402668 after ascending single IV doses.&#xD;
&#xD;
        -  The pharmacodynamics (PD) of GZ402668 after ascending single IV doses.&#xD;
&#xD;
        -  The PK parameters of GZ402668 after ascending single SC doses.&#xD;
&#xD;
        -  The PD of GZ402668 after ascending single SC doses.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total study duration from screening for a patient can be approximately up to 8 weeks.&#xD;
&#xD;
      Upon completion of this trial, patients treated with GZ402668 will be required to enroll in a&#xD;
      4 year safety follow-up study for continued safety observation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment emergent adverse events</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>maximum concentration (Cmax)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>area under curve (AUC)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with lymphocyte depletion</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with anti-drug antibodies</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with injection site reactions</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with corrected QT interval (QTcF) prolongation</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Progressive Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Dose 1 IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GZ402668 dose 1 intravenous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2 IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GZ402668 dose 2 intravenous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3 IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GZ402668 dose 3 intravenous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3 SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GZ402668 dose 3 subcutaneous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 4 SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GZ402668 dose 4 subcutaneous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 5 SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GZ402668 dose 5 subcutaneous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo SC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo subcutaneous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo IV</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo intravenous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GZ402668</intervention_name>
    <description>Pharmaceutical form:solution Route of administration: intravenous</description>
    <arm_group_label>Dose 1 IV</arm_group_label>
    <arm_group_label>Dose 2 IV</arm_group_label>
    <arm_group_label>Dose 3 IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Pharmaceutical form:solution Route of administration: intravenous</description>
    <arm_group_label>Placebo IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GZ402668</intervention_name>
    <description>Pharmaceutical form:solution Route of administration: subcutaneous</description>
    <arm_group_label>Dose 3 SC</arm_group_label>
    <arm_group_label>Dose 4 SC</arm_group_label>
    <arm_group_label>Dose 5 SC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Pharmaceutical form:solution Route of administration: subcutaneous</description>
    <arm_group_label>Placebo SC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acyclovir</intervention_name>
    <description>Pharmaceutical form:tablet Route of administration: oral</description>
    <arm_group_label>Dose 1 IV</arm_group_label>
    <arm_group_label>Dose 2 IV</arm_group_label>
    <arm_group_label>Dose 3 IV</arm_group_label>
    <arm_group_label>Dose 3 SC</arm_group_label>
    <arm_group_label>Dose 4 SC</arm_group_label>
    <arm_group_label>Dose 5 SC</arm_group_label>
    <arm_group_label>Placebo IV</arm_group_label>
    <arm_group_label>Placebo SC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Male or female adult with a diagnosis of progressive multiple sclerosis (MS) including&#xD;
             primary progressive MS, secondary progressive MS, and progressive relapsing MS.&#xD;
&#xD;
          -  Aged between 18 and 65 years, inclusive.&#xD;
&#xD;
          -  Body weight greater than 40.0 kg.&#xD;
&#xD;
          -  Female patient of child bearing potential must use 2 highly effective contraception&#xD;
             methods.&#xD;
&#xD;
          -  Male patient, whose partners are of childbearing potential (including lactating&#xD;
             women), must accept to use, during sexual intercourse, 2 highly effective&#xD;
             contraception methods. Male patient, whose partners are pregnant, must use, during&#xD;
             sexual intercourse, a condom from the inclusion up to 4 months after investigational&#xD;
             medicinal product administration.&#xD;
&#xD;
          -  Male patient who has agreed not to donate sperm for 4 months after product&#xD;
             administration.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Significant medical diseases or conditions, including poorly controlled hypertension,&#xD;
             cardiovascular disease, inflammatory disorders, immunodeficiency, autoimmune disease,&#xD;
             renal failure, liver dysfunction, cancer (except treated basal skin cell carcinoma),&#xD;
             or active infection.&#xD;
&#xD;
          -  Frequent headaches and/or migraine, recurrent nausea and/or vomiting.&#xD;
&#xD;
          -  History or presence of drug or alcohol abuse.&#xD;
&#xD;
          -  Smoking more than 5 cigarettes or equivalent per day.&#xD;
&#xD;
          -  If female, pregnancy, lactating, or breast-feeding.&#xD;
&#xD;
          -  Patients with relapsing-remitting MS.&#xD;
&#xD;
          -  Lymphocyte counts below the lower limit of normal.&#xD;
&#xD;
          -  Treatment with natalizumab, methotrexate, azathioprine, or cyclosporine in the past 6&#xD;
             months.&#xD;
&#xD;
          -  Treatment with mitoxantrone, cyclophosphamide, cladribine, rituximab or any other&#xD;
             immunosuppressant or cytotoxic therapy (other than steroids) in the last 12 months, or&#xD;
             determined by the treating physician to have residual immune suppression from these&#xD;
             treatments.&#xD;
&#xD;
          -  Treatment with glatiramer acetate or interferon beta in the past 4 weeks.&#xD;
&#xD;
          -  Treatment with fingolimod within the past 2 months.&#xD;
&#xD;
          -  Treatment with dimethyl fumarate in past 4 weeks.&#xD;
&#xD;
          -  Treatment with teriflunomide within the past 12 months unless patient has completed an&#xD;
             accelerated clearance with cholestyramine.&#xD;
&#xD;
          -  Previous treatment with alemtuzumab.&#xD;
&#xD;
          -  Live, attenuated vaccine within 3 months prior to the randomization visit, such as&#xD;
             varicella-zoster, oral polio, and rubella vaccines.&#xD;
&#xD;
          -  Clinically significant abnormality in thyroid function.&#xD;
&#xD;
          -  Inability to undergo magnetic resonance imaging with gadolinium administration.&#xD;
&#xD;
          -  Hypersensitivity or contraindication to acyclovir.&#xD;
&#xD;
          -  Known bleeding disorder.&#xD;
&#xD;
          -  Significant autoimmune disease.&#xD;
&#xD;
          -  Active infection or at high risk for infection.&#xD;
&#xD;
          -  Latent or active tuberculosis.&#xD;
&#xD;
          -  Major psychiatric disorder that is not adequately controlled by treatment.&#xD;
&#xD;
          -  Epileptic seizures that are not adequately controlled by treatment.&#xD;
&#xD;
          -  Prior history of invasive fungal infections.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 276001</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>October 31, 2014</study_first_submitted>
  <study_first_submitted_qc>November 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2014</study_first_posted>
  <last_update_submitted>April 12, 2016</last_update_submitted>
  <last_update_submitted_qc>April 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acyclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

